Nanox Partners Beilinson Hospital to Study Nanox.ARC

Nanox Partners Beilinson Hospital to Study Nanox.ARC

By, Admin 4 March 2024

Nanox and Beilinson Hospital Announce Collaboration to Study Diagnostic Capabilities of Nanox.ARC for Detection of Lung and Chest

Diseases

First patients in clinical study at Beilinson Hospital were scanned with the Nanox.ARC, a stationary X-ray system that produces 3D tomographic images

Study may help determine clinical utility of additional information provided by tomographic imaging for a range of pulmonary conditions NANO-X IMAGING LTD an innovative medical imaging technology company, and Beilinson Hospital, a leading Israeli hospital and part of Rabin Medical Center, owned and operated by Israel’s largest healthcare organization, Clalit Health Services, today announced their collaboration to conduct a clinical study evaluating the Nanox.ARC 3D imaging system in a clinical outpatient setting at Beilinson Hospital. The study will specifically assess the diagnostic capabilities of the Nanox.ARC’s tomographic imaging system compared with conventional two-dimensional radiography for detection of lung and chest disease in adults. Such a study may help determine the clinical utility of the additional information provided by the 3D tomographic imaging, potentially preventing the need for more advanced imaging and exposure to additional radiation.

About Nanox.ARC

  • The Nanox.ARC is a digital tomosynthesis system that uses multiple sources of X-rays to produce a three-dimensional, or tomographic, image of the body. 
  • Compared to similar X-ray tomosynthesis based devices, Nanox.ARC has a smaller footprint, utilizes a cold cathode system which does not require the high level of heat needed in a standard “hot cathode” X-ray, and has the potential to be a cost-effective and scalable imaging solution in healthcare settings that would otherwise be unable to deploy traditional medical imaging equipment.
  • As part of the study, the Nanox.ARC is being used to scan patients with abnormal lung conditions at Beilinson, one of the world's top academic medical centers and an institution that has pioneered advancements in radiology. 
  • The study is being led by Professor Eli Atar, M.D., FSIR, Director of the Department of Imaging, and Dr. Ahuva Grubstein, M.D., Department of Diagnostic Radiology, both at Beilinson Hospital.

Previous Stdies

  • This study evaluating the Nanox.ARC is an addition to the existing collaboration between Nanox AI and Clalit, and the second study conducted with Beilinson Hospital. 
  • Previously, Beilinson conducted a study using Nanox AI’s HealthCCSng solution on routine chest CT scans to assess the impact of AI-based coronary artery calcium (CAC) measurements, and that ~40% of patients included in the study had previously undetected risk of a cardiovascular event. 
  • Nanox AI's HealthCCSng is an advanced AI-powered solution designed specifically to detect CAC, which is known as an early sign of cardiac disease. 
  • It utilizes medical imaging data from routine chest CT scans to automatically quantify and analyze coronary artery calcium category, providing crucial insights into potential cardiovascular risks.

Words from Nanox

“This collaboration with Beilinson Hospital will provide further clinical validation of the Nanox.ARC and enable us to develop a truly end-to-end, globally connected medical imaging solution to promote population health for those in greatest need,” said Erez Meltzer, CEO of Nanox. “We look forward to continuing our partnership with Beilinson as we initiate a study exploring the use of our innovative 3D Nanox.ARC imaging system to improve patient care.”

Words from Beilinson Hospital

“We are pleased to collaborate further with Nanox on this important study of their novel digital tomosynthesis technology,” said Professor Eli Atar, M.D., Director of the Department of Imaging, Beilinson Hospital. “This technology shows promise to expand clinicians’ capabilities for more precise readings and earlier detection across a range of pulmonary conditions. With further validation, we believe Nanox.ARC could meaningfully augment radiology departments’ capacity to provide the highest standard of care while managing imaging volume demands.”

About Nanox

  • Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. 
  • Nanox’s vision is to increase access, reduce costs and enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment, which Nanox believes is key to helping people achieve better health outcomes, and, ultimately, to save lives. 
  • The Nanox ecosystem includes Nanox.ARC— a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic disease (Nanox AI); a cloud-based infrastructure (Nanox.CLOUD); and a proprietary decentralized marketplace, through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts; and a comprehensive teleradiology services platform (Nanox.MARKETPLACE). 
  • Together, Nanox’s products and services create a worldwide, innovative and comprehensive solution that connects medical imaging solutions, from scan to diagnosis. For more information, please visit www.nanox.vision.

About Beilinson Hospital

  • As one of Israel’s largest and most prominent medical centers, Beilinson leads the charge in implementing new innovative treatments while maintaining the highest standards of quality medical and nursing care. 
  • Since 1936, Beilinson Hospital in Petach Tikvah has grown to serve more than 500,000 patients annually. The 1,300-bed hospital in Central Israel, staffed by a team of 4,500 medical and support professionals, has 37 operating rooms, performs over 70-percent of all organ transplants in Israel, and welcomes more than 9,500 babies annually into the world through its robust labor and delivery department.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!